HISTOLOGICAL RESULTS IN TRANSGENDER INDIVIDUALS ASSIGNED TO FEMALES AT BIRTH UNDERGOING GENDER AFFIRMATION SURGERY AND IN TESTOSTERONE THERAPY
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Nov 26, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the health of reproductive organs in transgender men (people assigned female at birth) who are undergoing gender affirmation surgery, particularly those who are also on testosterone therapy. The researchers want to learn more about how testosterone affects these organs over time and to see if there are any common health issues, like benign (non-cancerous) or cancerous conditions, in these individuals.
To participate in this study, you need to be over 18 years old, have a diagnosis of gender incongruence, and be planning to have gender affirmation surgery that includes the removal of reproductive organs (hysterectomy) while also receiving testosterone therapy. The trial is currently not recruiting participants, but if eligible, you would have the opportunity to contribute to important research that could improve understanding and care for transgender individuals.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • gender incongruence diagnosis
- • people assigned female at birth
- • age \>18 years
- • gender affirming surgery with hysterectomy
- • testosterone therapy
- Exclusion Criteria:
- • previous gynecological surgery
- • previous gynecological disorder diagnosis
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, Emilia Romagna, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported